Sign In
Buy TRVI
$13.45
-0.0500 (-0.370%)
At Close: Jun 03, 2026
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer
07:30am, Thursday, 04'th Dec 2025
Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth NEW HAVEN, Conn. , Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clin
Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond
02:16pm, Wednesday, 03'rd Dec 2025
Trevi Therapeutics (TRVI) is initiated with a "Buy" rating, driven by its lead asset Haduvio's advancement toward phase 3 testing for chronic cough in IPF. Company's Haduvio demonstrated statistically
Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up on Strong Earnings
02:19am, Saturday, 15'th Nov 2025
Trevi Therapeutics, Inc. (NASDAQ: TRVI - Get Free Report)'s stock price gapped up before the market opened on Friday following a stronger than expected earnings report. The stock had previously closed
Trevi Therapeutics, Inc. (TRVI) Q3 2025 Earnings Call Transcript
09:21pm, Thursday, 13'th Nov 2025
Trevi Therapeutics, Inc. ( TRVI ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Jennifer Good - Co-Founder, CEO, President, Interim Principal Financial Officer & Director Ja
Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
04:05pm, Thursday, 13'th Nov 2025
Company preparing to initiate comprehensive Phase 3 program for chronic cough in patients with idiopathic pulmonary fibrosis in first half of 2026 Company ended the third quarter of 2025 with $194.9 m
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025
04:05pm, Thursday, 06'th Nov 2025
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn.
Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference
07:30am, Tuesday, 04'th Nov 2025
Fireside Chat with Management on Tuesday, November 11, 2025, at 3:20 p.m. ET NEW HAVEN, Conn.
Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting
07:30am, Wednesday, 08'th Oct 2025
Professor Philip Molyneaux will give an oral presentation on the key efficacy and safety results from the Phase 2b CORAL trial of nalbuphine ER for the treatment of chronic cough in patients with idio
NEW HAVEN, Conn. , Sept. 18, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphi
Trevi Therapeutics, Inc. (TRVI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
07:15pm, Tuesday, 09'th Sep 2025
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:05 PM EDT Company Participants Jennifer Good - Co-Founder, CEO, President, Interim P
Trevi Therapeutics to Participate in Upcoming September Conferences
07:30am, Thursday, 28'th Aug 2025
NEW HAVEN, Conn. , Aug. 28, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine
Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call Transcript
01:47pm, Friday, 08'th Aug 2025
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants g - Corporate Participant e - Corporate Participant Farrell Simon - Chief Commer
Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
04:05pm, Thursday, 07'th Aug 2025
Announced positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF Closed $115 million underwritten offering with expected cash runway
Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025
04:05pm, Thursday, 31'st Jul 2025
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn.
Trevi Therapeutics to Participate in Upcoming August Conferences
07:30am, Tuesday, 29'th Jul 2025
NEW HAVEN, Conn. , July 29, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphin
